Completed PHASE4 INTERVENTIONAL 2-arm NCT02380157

Blood Pressure Regulation - Role of Potassium

Oral Potassium Supplementation in Healthy Men - Interactions With the Renin-angiotensin-aldosterone System and the Sympathetic Nervous System

Sponsor: Danish Heart Foundation

Conditions Blood Pressure Hypertension

Interventions Kaleorid, 750mg (trade name), Potassium chloride (active substance) Placebo

Updated 6 times since 2017 Last updated: Jan 5, 2017 Started: Mar 31, 2015 Primary completion: Dec 31, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02380157, this PHASE4 trial focuses on Blood Pressure and Hypertension and remains completed. Sponsored by Danish Heart Foundation, it has been updated 6 times since 2015, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

Status: Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE4

First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Danish Heart Foundation
Glostrup University Hospital, Copenhagen

Data source: Glostrup University Hospital, Copenhagen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Glostrup, Copenhagen, Denmark